Which drug is typically prescribed for a patient with diabetes insipidus quizlet?

Continuing Education Activity

Diabetes insipidus (DI) is a disease process that results in either decreased release of antidiuretic hormone (ADH, also known as vasopressin or AVP) or decreased response to ADH, causing electrolyte imbalances. There are two types of diabetes insipidus, central and nephrogenic, and each has congenital and acquired causes. This activity reviews the etiology, presentation, evaluation, and management of diabetes insipidus and reviews the interprofessional team's role in evaluating, diagnosing, and managing the condition.

Objectives:

• Review the pathophysiology of the two primary categories of diabetes insipidus causes in each category.

• Outline the factors involved in evaluating a patient with suspected diabetes insipidus, including laboratory analysis.

• Describe the treatment options for diabetes insipidus, depending on the specific etiology.

• Explain the importance of improving coordination among the interprofessional team to enhance care for patients affected by diabetes insipidus.

Access free multiple choice questions on this topic.

Introduction

Diabetes insipidus (DI) is a disease process that results in either decreased release of or response to antidiuretic hormone (ADH, also known as vasopressin or AVP), which can cause electrolyte imbalances.[1][2] There are two types of diabetes insipidus, central and nephrogenic, and each has congenital and acquired causes. There is a passage of large volumes of dilute urine (less than 300m Osm/kg) in all cases.

Etiology

Idiopathic central diabetes insipidus is the most common cause, in which no identifiable cause was determined. The congenital form of central diabetes insipidus is rare and is associated with hypothalamus malformations, defects in ADH precursor synthesis, or ADH deficiency.[3][4]

Acquired forms of central diabetes insipidus include autoimmune and vascular diseases, sarcoidosis, craniopharyngioma, Langerhans Cell Histiocytosis, surgery, trauma, structural malformations, metastasis, hypoxic brain injury, or ischemia.

About 20% of patients who undergo neurosurgery will present with diabetes insipidus.

The congenital form of nephrogenic diabetes insipidus is associated with mutations in either the AVPR2 or AQP2 gene. AVPR2 receptor defects are the source of 90% of congenital nephrogenic diabetes insipidus form of nephrogenic diabetes insipidus are more common and can stem from multiple drug treatments, including lithium, antibiotics, antifungals, and antineoplastic agents. Other acquired causes include renal disease, sickle cell disease, obstructive uropathy, pregnancy, craniopharyngioma surgery, and electrolyte disturbances such as hypokalemia and hypercalcemia.

Epidemiology

Diabetes insipidus is an uncommon disease process with a low prevalence of 3 cases per 100,000 population.[5] In clinical practice, congenital forms of diabetes insipidus constitute less than 10% of patient cases.

Pathophysiology

Water balance is regulated by ADH, thirst, and kidney function. ADH is produced by the posterior pituitary and released into the blood supply via the inferior hypophyseal arteries. Subsequently, ADH targets the kidney and binds to V2-receptors on the renal collecting tubule. This leads to a signaling cascade of Gs-adenyl cyclase system activation, which increases cyclic 3',5'-adenosine monophosphate (cAMP), leading to the phosphorylation of preformed AQP2 water channels. The AQP2 channels translocate to the cell membrane and promote water flow by an osmotic gradient from the lumen into the cells of the collecting duct.[6][7][8]

In central diabetes insipidus, there is a deficiency of ADH. In nephrogenic diabetes insipidus, ADH is available, but there is a lack of response by the kidneys.

Apelin is a diuretic neuropeptide that has been shown to counteract ADH and may play a role in regulating fluid balance. In lactating mice, water deprivation demonstrated an increase in ADH release and depletion of hypothalamic stores, in conjunction with decreased apelin concentrations and increased hypothalamic stores.

History and Physical

The most common findings in patients with diabetes insipidus are polydipsia, polyuria, and nocturia.

Polyuria is defined as a urine output of more than 3 L/day in adults or 2 L/m2 in children. In children, symptoms can be nonspecific, and they may present with severe dehydration, constipation, vomiting, fevers, irritability, failure to thrive, and growth retardation. In patients with central nervous system (CNS) tumors, headaches, and visual defects may present in addition to the classic symptoms.

Additional symptoms in patients with diabetes insipidus may include weakness, lethargy, fatigue, and myalgias.

In mentally ill patients, extreme thirst is a good indicator of the problem.

The differentials for polyuria should include primary polydipsia and uncontrolled diabetes mellitus.

Evaluation

Calculate the plasma osmolality: 2[Na+] + [Glucose]/18 + [BUN]/2.8

Calculate the total 24-hour urine volume to confirm polyuria. Obtain baseline values of plasma electrolytes, random serum, and urine osmolality.[9][10][11][12]

To differentiate central and nephrogenic diabetes insipidus, perform a water deprivation test and desmopressin (DDAVP) trial. Typically a 7-hour deprivation test is adequate to diagnose diabetes insipidus. Primary polydipsia may require longer dehydration periods.

In adults, the water restriction test should be discontinued when one of the following is reached:

• Urine osmolality reaches the normal reference range.

• Urine osmolality is stable on two to three consecutive hourly measurements, even with rising plasma osmolality.

• Plasma osmolality greater than 295 mosmol/kg to 300 mosmol/kg

• Plasma Na greater than 145 mEq

If nephrogenic diabetes insipidus is suspected in newborns and young infants, the diagnostic test of choice is DDAVP (1 mcg subcutaneously or intravenously over 20 minutes, maximum dose of 0.4 mcg/kg).

In children, the water deprivation test should be closely monitored. If one of the following endpoints are reached, discontinue the trial:

• Urine osmolality reaches the normal reference range.

• Plasma osmolality greater than 295 mosmol/kg to 300 mosmol/kg

• Plasma sodium greater than 145 meq/L

• Loss of 5% of body weight or signs of volume depletion

The water deprivation trial is most accurate when DDAVP is not given. After water deprivation, studies have demonstrated that desmopressin can increase urine osmolality by greater than 100% incomplete central diabetes insipidus and up to 50% in partial central diabetes insipidus.

In cases of nephrogenic diabetes insipidus, water deprivation suboptimally increases urine osmolality. DDAVP minimally increases urine osmolality in partial nephrogenic diabetes insipidus, with no increase in urine osmolality in complete nephrogenic diabetes insipidus.

Central diabetes insipidus is diagnosed when there is evidence of plasma hyperosmolality (greater than 300 mosm/l), urine hyperosmolality (less than 300 mosm/l or urine/plasma osmolality less than 1), polyuria (urinary volume greater than 4 mL/kg/hr to 5 mL/kg/hr for two consecutive hours after surgery).

Copeptin and AQP2 have also been utilized to differentiate nephrogenic and central diabetes insipidus. In central diabetes insipidus, AQP2 increases with DDAVP administration. On the contrary, in patients with nephrogenic diabetes insipidus, the AQP2 excretion does not increase after DDAVP administration.

When suspecting a structural cause of diabetes insipidus, MRI imaging can identify malformations of the posterior pituitary.

Treatment / Management

DDAVP, an ADH analog, can be administered orally, intranasally, subcutaneously, or intravenously. In adults, the dose is ten mcg by nasal insufflation or 4 mcg subcutaneously or intravenously. In newborns or very young infants, the dose is one mcg subcutaneously or intravenously over 20 minutes with a maximum dose of 0.4 mcg/kg.

It is essential to replete fluid losses in diabetes insipidus, as some patients may have thirst impairment and will not respond adequately to water intake.[13][14][15]

Central Diabetes Insipidus

The preferred therapy is DDAVP. Typically, therapy is maintained for the duration of central diabetes insipidus, which varies depending on the cause. The minimum dose should be administered to control polyuria adequately.

It is important to monitor hyponatremia, as water retention can lead to sodium concentration changes that may cause brain injury. The patients and families should be educated to observe for symptoms of nausea, vomiting, lethargy, headaches, confusion, seizures, and coma.

Other treatment options for central diabetes insipidus include a low-solute diet (low salt, low protein), thiazide diuretics, chlorpropamide, carbamazepine, and non-steroidal anti-inflammatory drugs (NSAID).

DDAVP is considered safe during pregnancy.

N ephrogenic Diabetes Insipidus

The first step is to correct the underlying cause. If possible, discontinue the offending agent, such as lithium.

A low-solute diet may decrease urine output. The lower amount of total solutes ingested, the lower the urine volume that will be excreted.

Thiazide diuretics may be used in conjunction with dietary changes. The mechanism of administering a diuretic for polyuria is to promote the reduction of urine volume, which triggers the endogenous release of aldosterone. By having less water delivered distally, there would be less water loss in the collecting tubule, where ADH targets its effects.

Other treatment options include DDAVP and NSAIDs. NSAIDs inhibit prostaglandin synthesis, which has antagonistic effects on ADH.

Differential Diagnosis

• Hypercalcemia

• Hypokalemia

• Sickle cell anemia

• Histiocytosis

• Diabetes mellitus

Prognosis

The prognosis for most patients with DI is excellent as long as the underlying primary cause can be treated. Lithium discontinuation can restore normal kidney function, but the nephrogenic DI may be permanent in some patients. 

As long as the individual has access to water, mortality can be avoided. However, in children and older patients, the condition can lead to cardiovascular collapse, fever, and hypernatremia.

Complications

Without medical treatment, the potential diabetes insipidus complications include:

• Chronic dehydration

• Tachycardia

• Decreased temperature

• Hypotension

• Weight loss

• Fatigue

• Headaches

• Kidney damage

• Brain damage

Deterrence and Patient Education

Patients should be warned about traveling and be prepared to manage diarrhea and vomiting to avoid dehydration. The patient should have easy access to water and avoid traveling to hot destinations where medical care may not always be available.

Pearls and Other Issues

Patients with significant electrolyte abnormalities should be closely monitored and admitted to the hospital.

Enhancing Healthcare Team Outcomes

There are many causes of DI, and the disorder is best managed by an interprofessional team that includes the primary care provider, nurse practitioner/physician assistant, internist, and pharmacist. Patient education is crucial. The key is to hydrate and replace the electrolytes and then manage the primary condition causing DI. The pharmacist should keep track of all medications that can cause DI and make the appropriate recommendations to the clinician. The nurse should educate the patient on traveling to hot destinations because dehydration can result in exacerbating the symptoms. If possible, travel should be avoided until the condition is treated. In post-operative patients, the specific gravity of the urine should be monitored before administering desmopressin. Also, blood should be drawn regularly, and levels of electrolytes monitored.

Outcome

The outlook for patients with DI depends on the cause. For benign causes, the prognosis is good, but if the cause is a malignancy, then the prognosis is guarded.[16][6] With an interprofessional team approach, outcomes can improve. [Level 5]

Review Questions

References

Guerrero-Pérez F, Marengo AP, Vidal N, Iglesias P, Villabona C. Primary tumors of the posterior pituitary: A systematic review. Rev Endocr Metab Disord. 2019 Jun;20(2):219-238. [PubMed: 30864049]

Calina D, Docea AO, Golokhvast KS, Sifakis S, Tsatsakis A, Makrigiannakis A. Management of Endocrinopathies in Pregnancy: A Review of Current Evidence. Int J Environ Res Public Health. 2019 Mar 04;16(5) [PMC free article: PMC6427139] [PubMed: 30836653]

Tabibzadeh N, Vrtovsnik F, Serrano F, Vidal-Petiot E, Flamant M. [Chronic metabolic and renal disorders related to lithium salts treatment]. Rev Med Interne. 2019 Sep;40(9):599-608. [PubMed: 30827493]

Ranieri M, Di Mise A, Tamma G, Valenti G. Vasopressin-aquaporin-2 pathway: recent advances in understanding water balance disorders. F1000Res. 2019;8 [PMC free article: PMC6364380] [PubMed: 30800291]

Saborio P, Tipton GA, Chan JC. Diabetes insipidus. Pediatr Rev. 2000 Apr;21(4):122-9; quiz 129. [PubMed: 10756175]

Harrois A, Anstey JR. Diabetes Insipidus and Syndrome of Inappropriate Antidiuretic Hormone in Critically Ill Patients. Crit Care Clin. 2019 Apr;35(2):187-200. [PubMed: 30784603]

Atallah-Yunes SA, Clark J, Samanani S, Soe M. Small Cell Lung Cancer with Pituitary Metastasis Presenting as Secondary Adrenal Insufficiency: A Case Report and Literature Review. Am J Case Rep. 2019 Feb 17;20:207-211. [PMC free article: PMC6388645] [PubMed: 30772889]

Meyfroidt G, Gunst J, Martin-Loeches I, Smith M, Robba C, Taccone FS, Citerio G. Management of the brain-dead donor in the ICU: general and specific therapy to improve transplantable organ quality. Intensive Care Med. 2019 Mar;45(3):343-353. [PMC free article: PMC7095373] [PubMed: 30741327]

Davis J, Desmond M, Berk M. Lithium and nephrotoxicity: a literature review of approaches to clinical management and risk stratification. BMC Nephrol. 2018 Nov 03;19(1):305. [PMC free article: PMC6215627] [PubMed: 30390660]

Baldeweg SE, Ball S, Brooke A, Gleeson HK, Levy MJ, Prentice M, Wass J., Society for Endocrinology Clinical Committee. SOCIETY FOR ENDOCRINOLOGY CLINICAL GUIDANCE: Inpatient management of cranial diabetes insipidus. Endocr Connect. 2018 Jul;7(7):G8-G11. [PMC free article: PMC6013691] [PubMed: 29930026]

Lobatto DJ, de Vries F, Zamanipoor Najafabadi AH, Pereira AM, Peul WC, Vliet Vlieland TPM, Biermasz NR, van Furth WR. Preoperative risk factors for postoperative complications in endoscopic pituitary surgery: a systematic review. Pituitary. 2018 Feb;21(1):84-97. [PMC free article: PMC5767215] [PubMed: 28916976]

Andrysiak-Mamos E, Sagan K, Sagan L, Sowińska-Przepiera E, Syrenicz A. Cystic lesions of the sellar-suprasellar region - diagnosis and treatment. Endokrynol Pol. 2018;69(2):212-228. [PubMed: 29952427]

Hunter JD, Calikoglu AS. Etiological and clinical characteristics of central diabetes insipidus in children: a single center experience. Int J Pediatr Endocrinol. 2016;2016:3. [PMC free article: PMC4750251] [PubMed: 26870137]

Arambewela MH, Somasundaram NP, Garusinghe C. Extreme hypernatremia as a probable cause of fatal arrhythmia: a case report. J Med Case Rep. 2016 Oct 01;10(1):272. [PMC free article: PMC5045618] [PubMed: 27716387]

Lamas C, del Pozo C, Villabona C., Neuroendocrinology Group of the SEEN. Clinical guidelines for management of diabetes insipidus and syndrome of inappropriate antidiuretic hormone secretion after pituitary surgery. Endocrinol Nutr. 2014 Apr;61(4):e15-24. [PubMed: 24588923]

Asemota AO, Gallia GL. Impact of frailty on short-term outcomes in patients undergoing transsphenoidal pituitary surgery. J Neurosurg. 2019 Feb 22;132(2):360-370. [PubMed: 30797214]

Which drug class is indicated for diabetes insipidus?

Is vasopressin used to treat diabetes insipidus?

Which class of diuretics is effective in diabetes insipidus?

What is the medication of choice for a child with diabetes insipidus?